ADAPTIN BIO
LIVE

Serial Number

98746952

Owner

Adaptin Bio, Inc.

Attorney

Devon E. White

Filing Date

Sep 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ADAPTIN BIO Trademark

Serial Number: 98746952

ADAPTIN BIO is a trademark filed by Adaptin Bio, Inc. on September 12, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Adaptin Bio, Inc. (2 trademarks)

3540 Toringdon Way, Suite 200 #250
Charlotte, NC 28277

Entity Type: 03

Trademark Details

Filing Date

September 12, 2024

Registration Date

Not Registered

Published for Opposition

August 26, 2025

Goods & Services

Biological preparations for treatment of cancers, central nervous system diseases and autoimmune disorders; Medical preparations and pharmaceuticals for treatment of cancers, central nervous system diseases and autoimmune disorders; Drug delivery agents in the form of an injectable liquid suspension that facilitate delivery of pharmaceutical preparations; Drug delivery platform, namely, drug delivery agents in the nature of cellular products being an injectable liquid suspension that facilitates delivery of pharmaceuticals; Pharmaceutical preparations for the treatment of cancers, central nervous system diseases and autoimmune disorders using compounds comprising of manipulated immune cells

Research in the field of biotechnology and pharmaceutical development; Research and development of platform technologies for delivery of therapies; Research and development of platform technologies for delivery of antibody therapies, cell therapies and pharmaceuticals; Research and development regarding the use of immune system cells to discover, research and develop novel platform technologies for delivery of therapies and pharmaceuticals; Pharmaceutical research and development for the treatment of cancers, neurological diseases, and neurological disorders and autoimmune disorders; Scientific research in the field of drug delivery platforms, cell therapies and pharmaceuticals; Pharmaceutical research services; Research and development of pharmaceutical preparations for treatment of cancers, neurological diseases and disorders and autoimmune diseases; Research and development in the fields of pharmaceuticals and biotechnology; Research and development regarding the delivery of drug therapies across the blood-brain barrier and other physiological barriers; Research and development regarding the delivery of drug and cell therapies to targeted body tissue; Research and development regarding the identification and targeting of specific cells for drug therapies

Biological preparations for use in the manufacture of pharmaceuticals

Filing History

TEAS REQUEST TO DIVIDE RECEIVED
Apr 16, 2026 ERTD
SOU TEAS EXTENSION RECEIVED
Apr 16, 2026 EEXT
TEAS STATEMENT OF USE RECEIVED
Apr 16, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 21, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 24, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 23, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 23, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 23, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 23, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 18, 2025 GNFN
FINAL REFUSAL E-MAILED
Jul 18, 2025 GNFR
FINAL REFUSAL WRITTEN
Jul 18, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 1, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 1, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 1, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 1, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 13, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2025 NWOS
NEW APPLICATION ENTERED
Sep 12, 2024 NWAP